



Microbiome Dx Genetic Analysis announces important patent approval enhancing the use of GA-map® in Canada

OSLO, NORWAY – February 12, 2026: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) announces that its important patent application CA2980637) has now been allowed for grant in Canada. The important patent entitled “METHOD FOR DETERMINING GASTROINTESTINAL TRACT DYSBIOSIS” covers the Company’s unique algorithm incorporated in the GA-map® technology for profiling gut microbiota. GA has an active patent strategy covering all major geographical markets and has previously announced approval in EU, China and other countries for this patent.

The subject matter of this family of patents relates to the sophisticated algorithms developed by Genetic Analysis that analyze and characterize gut microbiota in relation to healthy populations. The invention concerns the diagnosis, monitoring and/or characterization of diseases and conditions associated with perturbations in the microbiota of the gastrointestinal tract (GI). More specifically the invention provides means by which the state of the microbiota may be assessed and deviations from the normal state (normobiosis) may be determined in a manner which is straightforward to perform, reliable and robust and which is also flexible enough to be used with any technique for measuring levels of microorganisms in a GI tract sample.

The patent has been allowed for grant by the Canadian Intellectual Property Office. The required grant fee has been paid and the patent is expected to be formally issued in Q1 2026. The patent family claims priority from 27 March 2015 and will be in force until 2036.

CEO Ronny Hermansen comments:

“We are delighted to announce that our patent “A method for determining gastrointestinal tract dysbiosis” has been allowed in Canada. The approval further strengthens our intellectual property portfolio and is an important step forward in GA’s international expansion.”

For more information, please contact:

Ronny Hermansen, CEO

E-mail: rh@genetic-analysis.com

About Genetic Analysis:

Genetic Analysis AS (GA) is a science-based diagnostic company and pioneer in the human microbiome field with more than 15 years of expertise in research and product development. The unique GA-map® platform is based on a pre-determined multiplex targets approach specialized for simultaneous analysis of a large number of bacteria in one reaction. The test results are generated by utilizing the clinically validated cutting edge GA-map® software algorithm. This enables immediate results without the need for further bioinformatics work. GA’s vision is to become the leading company for standardized gut microbiota testing worldwide, and GA is committed to help unlocking and restoring the human microbiome through its state-of-the-art technology. GA employs a team of highly qualified employees with scientific backgrounds and competence in bioinformatics, molecular biology, and bioengineering.

For more information: www.genetic-analysis.com

Interested in reading more about GA's products? Please visit ga-map.com